[PDF][PDF] Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations
DA Pollyea, CD DiNardo, ML Arellano, A Pigneux… - Clinical Cancer …, 2022 - AACR
DA Pollyea, CD DiNardo, ML Arellano, A Pigneux, W Fiedler, M Konopleva, DA Rizzieri…
Clinical Cancer Research, 2022•AACRPurpose: To evaluate efficacy and safety of venetoclax+ azacitidine among treatment-naïve
patients with IDH1/2-mutant (mut) acute myeloid leukemia (AML). Patients and Methods:
Data were pooled from patients enrolled in a phase III study (NCT02993523) that compared
patients treated with venetoclax+ azacitidine or placebo+ azacitidine and a prior phase Ib
study (NCT02203773) where patients were treated with venetoclax+ azacitidine. Enrolled
patients were ineligible for intensive therapy due to age≥ 75 years and/or comorbidities …
patients with IDH1/2-mutant (mut) acute myeloid leukemia (AML). Patients and Methods:
Data were pooled from patients enrolled in a phase III study (NCT02993523) that compared
patients treated with venetoclax+ azacitidine or placebo+ azacitidine and a prior phase Ib
study (NCT02203773) where patients were treated with venetoclax+ azacitidine. Enrolled
patients were ineligible for intensive therapy due to age≥ 75 years and/or comorbidities …
Purpose
To evaluate efficacy and safety of venetoclax + azacitidine among treatment-naïve patients with IDH1/2-mutant (mut) acute myeloid leukemia (AML).
Patients and Methods
Data were pooled from patients enrolled in a phase III study (NCT02993523) that compared patients treated with venetoclax + azacitidine or placebo + azacitidine and a prior phase Ib study (NCT02203773) where patients were treated with venetoclax + azacitidine. Enrolled patients were ineligible for intensive therapy due to age ≥75 years and/or comorbidities. Patients on venetoclax + azacitidine received venetoclax 400 mg orally (days 1–28) and azacitidine (75 mg/m2; days 1–7/28-day cycle).
Results
In the biomarker-evaluable population, IDH1/2mut was detected in 81 (26%) and 28 (22%) patients in the venetoclax + azacitidine and azacitidine groups. Composite complete remission [CRc, complete remission (CR)+CR with incomplete hematologic recovery (CRi)] rates (venetoclax + azacitidine/azacitidine) among patients with IDH1/2mut were 79%/11%, median duration of remission (mDoR) was 29.5/9.5 months, and median overall survival (mOS) was 24.5/6.2 months. CRc rates among patients with IDH1/2 wild-type (WT) were 63%/31%, mDoR 17.5/10.3 months, and mOS 12.3/10.1 months. In patients with IDH1mut, CRc rates (venetoclax + azacitidine/azacitidine) were 66.7%/9.1% and mOS 15.2/2.2 months. In patients with IDH2mut, CRc rates were 86.0%/11.1% and mOS not reached (NR)/13.0 months. Patients with IDH1/2 WT AML treated with venetoclax + azacitidine with poor-risk cytogenetics had inferior outcomes compared with patients with IDH1/2mut, who had superior outcomes regardless of cytogenetic risk (mOS, IDH1/2mut: intermediate-risk, 24.5 months; poor-risk, NR; IDH1/2 WT: intermediate, 19.2 and poor, 7.4 months). There were no unexpected toxicities in the venetoclax + azacitidine group.
Conclusions
Patients with IDH1/2mut who received venetoclax + azacitidine had high response rates, durable remissions, and significant OS; cytogenetic risk did not mitigate the favorable outcomes seen from this regimen for IDH1/2mut.
See related commentary by Perl and Vyas, p. 2719
AACR